Helus Pharma is developing psychedelic drugs, including oral psilocin and intramuscular DMT, targeting major depressive disorder (MDD) and generalized anxiety disorder (GAD). Early clinical trials show promising efficacy and durability as adjunctive therapies, though based on small studies. The company is currently conducting a phase III trial for its oral psilocin candidate, HLP003, which could validate its clinical benefits and improve its market valuation. Despite risks in clinical development and commercialization, Helus Pharma's established psychedelic platform and the unmet needs in mental health create a potentially attractive investment opportunity.
PDD Holdings Inc. will report its Q2 2026 earnings on August 24, with expected EPS of $2.72 and revenue around $16.94 billion. Despite recent stock gains, analysts have mixed views, including an Underperform rating from BNP Paribas and a downgrade by...
JD Sports Fashion reported weaker-than-expected second-quarter sales, especially in North America, prompting a cut in its full-year profit guidance. This led to a nearly 15% drop in its stock price. Analysts from Citigroup, UBS, and Shore Capital mai...
Jones Lang LaSalle's CEO sold 2,000 shares worth over $773,000, yet major investors like BlackRock increased holdings significantly, showing confidence. BlackRock now owns over 10% of the company after a $1.45 billion stake purchase. Other firms also...
Wedbush increased its price target for Scholar Rock to $64 from $58 and kept an "Outperform" rating ahead of the FDA's September 30 decision on Scholar Rock's investigational SMA drug, apitegromab. This drug could be the first muscle-targeted therapy...
IM Cannabis Corp., a medical cannabis company operating in Israel and Germany, will conduct a 1-for-30 reverse stock split on August 27, 2026. This move aims to increase its share price, currently at $0.11, to meet the Nasdaq Capital Market's minimum...
